|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RNF220 |
Gene summary for RNF220 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RNF220 | Gene ID | 55182 |
| Gene name | ring finger protein 220 | |
| Gene Alias | C1orf164 | |
| Cytomap | 1p34.1 | |
| Gene Type | protein-coding | GO ID | GO:0003002 | UniProtAcc | Q5VTB9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55182 | RNF220 | HCC1 | Human | Liver | HCC | 7.30e-04 | 2.22e+00 | 0.5336 |
| 55182 | RNF220 | HCC2 | Human | Liver | HCC | 1.77e-14 | 2.88e+00 | 0.5341 |
| 55182 | RNF220 | Pt13.b | Human | Liver | HCC | 2.84e-03 | 1.01e-01 | 0.0251 |
| 55182 | RNF220 | S014 | Human | Liver | HCC | 5.02e-18 | 6.43e-01 | 0.2254 |
| 55182 | RNF220 | S015 | Human | Liver | HCC | 2.69e-16 | 6.96e-01 | 0.2375 |
| 55182 | RNF220 | S016 | Human | Liver | HCC | 4.40e-15 | 6.25e-01 | 0.2243 |
| 55182 | RNF220 | S027 | Human | Liver | HCC | 5.21e-08 | 8.61e-01 | 0.2446 |
| 55182 | RNF220 | S028 | Human | Liver | HCC | 5.13e-26 | 1.06e+00 | 0.2503 |
| 55182 | RNF220 | S029 | Human | Liver | HCC | 6.29e-27 | 1.26e+00 | 0.2581 |
| 55182 | RNF220 | C04 | Human | Oral cavity | OSCC | 4.48e-09 | 6.19e-01 | 0.2633 |
| 55182 | RNF220 | C21 | Human | Oral cavity | OSCC | 6.56e-26 | 7.40e-01 | 0.2678 |
| 55182 | RNF220 | C30 | Human | Oral cavity | OSCC | 8.77e-38 | 1.49e+00 | 0.3055 |
| 55182 | RNF220 | C43 | Human | Oral cavity | OSCC | 3.65e-03 | 2.20e-01 | 0.1704 |
| 55182 | RNF220 | C46 | Human | Oral cavity | OSCC | 5.09e-06 | 2.89e-01 | 0.1673 |
| 55182 | RNF220 | C51 | Human | Oral cavity | OSCC | 1.18e-03 | 4.20e-01 | 0.2674 |
| 55182 | RNF220 | C57 | Human | Oral cavity | OSCC | 5.03e-03 | 3.29e-01 | 0.1679 |
| 55182 | RNF220 | C06 | Human | Oral cavity | OSCC | 1.44e-02 | 8.44e-01 | 0.2699 |
| 55182 | RNF220 | C07 | Human | Oral cavity | OSCC | 1.49e-02 | 6.83e-01 | 0.2491 |
| 55182 | RNF220 | C08 | Human | Oral cavity | OSCC | 1.56e-07 | 3.33e-01 | 0.1919 |
| 55182 | RNF220 | LN22 | Human | Oral cavity | OSCC | 1.92e-05 | 4.90e-01 | 0.1733 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:00219159 | Esophagus | ESCC | neural tube development | 101/8552 | 152/18723 | 1.78e-07 | 2.79e-06 | 101 |
| GO:003011117 | Esophagus | ESCC | regulation of Wnt signaling pathway | 194/8552 | 328/18723 | 5.39e-07 | 7.14e-06 | 194 |
| GO:006007016 | Esophagus | ESCC | canonical Wnt signaling pathway | 180/8552 | 303/18723 | 9.15e-07 | 1.17e-05 | 180 |
| GO:006082817 | Esophagus | ESCC | regulation of canonical Wnt signaling pathway | 153/8552 | 253/18723 | 1.38e-06 | 1.67e-05 | 153 |
| GO:009026316 | Esophagus | ESCC | positive regulation of canonical Wnt signaling pathway | 69/8552 | 106/18723 | 4.22e-05 | 3.39e-04 | 69 |
| GO:003017716 | Esophagus | ESCC | positive regulation of Wnt signaling pathway | 87/8552 | 140/18723 | 6.18e-05 | 4.73e-04 | 87 |
| GO:00518658 | Esophagus | ESCC | protein autoubiquitination | 47/8552 | 73/18723 | 9.72e-04 | 4.93e-03 | 47 |
| GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
| GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
| GO:003011121 | Liver | HCC | regulation of Wnt signaling pathway | 180/7958 | 328/18723 | 3.62e-06 | 4.72e-05 | 180 |
| GO:006007021 | Liver | HCC | canonical Wnt signaling pathway | 162/7958 | 303/18723 | 7.00e-05 | 6.32e-04 | 162 |
| GO:006082821 | Liver | HCC | regulation of canonical Wnt signaling pathway | 137/7958 | 253/18723 | 1.15e-04 | 9.70e-04 | 137 |
| GO:003017721 | Liver | HCC | positive regulation of Wnt signaling pathway | 81/7958 | 140/18723 | 1.73e-04 | 1.36e-03 | 81 |
| GO:009026321 | Liver | HCC | positive regulation of canonical Wnt signaling pathway | 62/7958 | 106/18723 | 6.44e-04 | 3.99e-03 | 62 |
| GO:00219154 | Liver | HCC | neural tube development | 82/7958 | 152/18723 | 2.83e-03 | 1.33e-02 | 82 |
| GO:00518654 | Liver | HCC | protein autoubiquitination | 42/7958 | 73/18723 | 6.78e-03 | 2.73e-02 | 42 |
| GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
| GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RNF220 | SNV | Missense_Mutation | novel | c.46N>T | p.Leu16Phe | p.L16F | Q5VTB9 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-A7-A3RF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
| RNF220 | SNV | Missense_Mutation | c.1363G>A | p.Asp455Asn | p.D455N | Q5VTB9 | protein_coding | deleterious(0.04) | probably_damaging(0.956) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| RNF220 | SNV | Missense_Mutation | c.475N>C | p.Asp159His | p.D159H | Q5VTB9 | protein_coding | deleterious(0.04) | benign(0.308) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| RNF220 | SNV | Missense_Mutation | c.1156G>C | p.Glu386Gln | p.E386Q | Q5VTB9 | protein_coding | tolerated(0.06) | probably_damaging(0.932) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD | |
| RNF220 | SNV | Missense_Mutation | rs539612817 | c.223N>T | p.Arg75Trp | p.R75W | Q5VTB9 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| RNF220 | SNV | Missense_Mutation | novel | c.806C>A | p.Ser269Tyr | p.S269Y | Q5VTB9 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RNF220 | SNV | Missense_Mutation | rs377270177 | c.1511G>A | p.Arg504Gln | p.R504Q | Q5VTB9 | protein_coding | tolerated(0.09) | benign(0.045) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RNF220 | SNV | Missense_Mutation | rs539612817 | c.223C>T | p.Arg75Trp | p.R75W | Q5VTB9 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RNF220 | SNV | Missense_Mutation | rs776288553 | c.613N>G | p.Arg205Gly | p.R205G | Q5VTB9 | protein_coding | deleterious(0.05) | probably_damaging(0.931) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| RNF220 | SNV | Missense_Mutation | novel | c.917G>C | p.Arg306Pro | p.R306P | Q5VTB9 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |